Mark Munch Sells 2,000 Shares of Bruker (NASDAQ:BRKR) Stock

Bruker Corporation (NASDAQ:BRKR) VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the sale, the vice president owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Bruker Stock Performance

Shares of BRKR opened at $63.05 on Friday. The business’s 50 day moving average is $58.14 and its two-hundred day moving average is $49.82. Bruker Corporation has a 52-week low of $30.09 and a 52-week high of $65.30. The firm has a market cap of $9.61 billion, a price-to-earnings ratio of -90.07, a PEG ratio of 1.86 and a beta of 1.26. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts forecast that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s payout ratio is presently -28.57%.

Wall Street Analyst Weigh In

Several analysts have issued reports on BRKR shares. UBS Group began coverage on Bruker in a research note on Wednesday, September 9th. They set a “neutral” rating and a $65.00 price objective on the stock. Stifel Nicolaus set a $50.00 target price on Bruker in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a report on Monday, August 31st. TD Cowen restated a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Finally, Citigroup decreased their price objective on shares of Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $57.00.

Hedge Funds Weigh In On Bruker

A number of hedge funds and other institutional investors have recently bought and sold shares of BRKR. Pallas Capital Advisors LLC bought a new stake in Bruker in the 2nd quarter valued at about $570,746,000. Sculptor Capital LP grew its position in Bruker by 9.0% in the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock worth $118,112,000 after purchasing an additional 270,000 shares during the last quarter. Edmond DE Rothschild Holding S.A. bought a new position in Bruker in the 2nd quarter worth about $169,899,000. Dimensional Fund Advisors LP increased its stake in shares of Bruker by 23.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company’s stock valued at $84,556,000 after purchasing an additional 448,440 shares during the period. Finally, Franklin Resources Inc. raised its holdings in shares of Bruker by 317.7% during the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after buying an additional 1,756,460 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.